Paper Details

  1. Home
  2. Paper Details

Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.

Author: AndresMartin, NaglerMichael, NovakUrban, PellegriniLuca, SuterThomas

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review and meta-analysis investigated the risk of bleeding and atrial fibrillation associated with ibrutinib, a drug used to treat certain blood cancers. The results suggest that the risk of these events in clinical practice may be higher than estimated in randomized controlled trials.
Paper Details　
Original Abstract of the Article :
The use of ibrutinib is hampered by major bleeding events and atrial fibrillation. Speculating whether randomized controlled trials might underestimate the risk of adverse events in clinical practice, we conducted a systematic review and meta-analysis studying patients treated in any setting and ind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.critrevonc.2021.103238

データ提供：米国国立医学図書館（NLM）

Ibrutinib: A Balancing Act Between Benefits and Risks

This comprehensive research delves into the potential risks associated with ibrutinib treatment, specifically bleeding complications and atrial fibrillation. The study utilizes a systematic review and meta-analysis, combining data from multiple studies to provide a more robust understanding of the observed risks. The findings reveal a significant risk of bleeding events and atrial fibrillation among patients treated with ibrutinib, highlighting the importance of careful patient selection, close monitoring, and appropriate risk management strategies.

Navigating the Risks of Ibrutinib Treatment

This research highlights the need for careful consideration of the potential risks associated with ibrutinib treatment. The findings suggest that the risk of bleeding complications and atrial fibrillation may be higher in clinical practice than reported in randomized controlled trials. This underscores the importance of ongoing surveillance and research to identify potential risk factors and develop effective strategies for mitigating these risks.

Balancing the Benefits and Risks of Medications

This research reminds us that all medications, even those with significant therapeutic benefits, come with potential risks. It highlights the importance of a comprehensive and informed approach to medication management, including careful patient selection, individualized dosing, and ongoing monitoring to balance potential benefits against potential risks.

Dr.Camel's Conclusion

Like a camel navigating a treacherous desert landscape, the use of ibrutinib requires careful consideration of both potential benefits and risks. This study, like a vigilant guide, reveals the potential for bleeding complications and atrial fibrillation, highlighting the importance of a balanced approach to medication management. By understanding these risks, we can make informed decisions to optimize treatment outcomes and ensure patient safety.

Date :
  1. Date Completed 2021-03-08
  2. Date Revised 2021-03-08
Further Info :

Pubmed ID

33515702

DOI: Digital Object Identifier

10.1016/j.critrevonc.2021.103238

Related Literature

Article Analysis
・Side Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.